Grand Mal Seizure Market Size, Share, Growth, and Industry Analysis, By Type (Barbiturates, Hydantoin, Phenyltriazine, Iminostilbenes, Benzodiazepines, Aliphatic Carboxylic Acid, Others), By Application (Hospitals, Clinics, Academic and Research Centers, Others), Regional Insights and Forecast to 2035

Unique Information about the Grand Mal Seizure Market

Grand Mal Seizure Market size is anticipated to be worth USD 2449.79 million in 2026 and is expected to reach USD 3579.51 million by 2035 at a CAGR of 4.31%.

The Grand Mal Seizure Market represents a specialized segment of the global epilepsy therapeutics landscape focused on generalized tonic-clonic seizures, commonly known as grand mal seizures. According to neurological epidemiology estimates, approximately 50 million people worldwide live with epilepsy, and generalized tonic-clonic seizures account for nearly 25% to 35% of all seizure presentations. More than 80% of epilepsy cases occur in low- and middle-income countries, creating significant demand for accessible antiepileptic therapies. Treatment adherence remains a major focus, as studies indicate that approximately 30% of epilepsy patients experience uncontrolled seizures despite medication use. The Grand Mal Seizure Market Report highlights increasing adoption of combination therapies, with nearly 20% to 40% of patients requiring multidrug regimens to improve seizure control and reduce recurrence frequency.

The United States remains a major contributor to the Grand Mal Seizure Market Size due to high diagnosis rates and extensive access to neurological care. Approximately 3.4 million individuals in the United States live with epilepsy, including nearly 470,000 children aged 17 years and younger. Epidemiological assessments indicate that around 150,000 new epilepsy cases are diagnosed annually across the country. Generalized tonic-clonic seizures constitute approximately 30% of newly identified epilepsy presentations in tertiary care centers. Nearly 90% of U.S. epilepsy patients receive pharmacological treatment, while specialized epilepsy centers exceed 250 facilities nationwide. The Grand Mal Seizure Market Analysis further identifies that close to 1 in 26 Americans are expected to develop epilepsy during their lifetime, reinforcing sustained demand for diagnosis, monitoring, and therapeutic interventions.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: Approximately 35% of epilepsy diagnoses involve generalized seizures, 70% of patients achieve seizure control through medication, 30% require treatment modification, and adherence improvements exceeding 25% contribute significantly to therapeutic demand within the Grand Mal Seizure Market Growth landscape.
• Major Market Restraint: Nearly 30% of patients exhibit drug-resistant epilepsy, adverse-event discontinuation affects approximately 15% of users, treatment nonadherence exceeds 40% in selected populations, and delayed diagnosis impacts close to 20% of affected individuals.
• Emerging Trends: About 45% of neurologists increasingly prefer newer-generation antiepileptic agents, telemedicine utilization has surpassed 35%, wearable seizure monitoring adoption approaches 18%, and precision medicine initiatives influence approximately 22% of treatment pathways.
• Regional Leadership: North America accounts for approximately 38% of global therapeutic utilization, Europe contributes nearly 28%, Asia-Pacific represents around 24%, while Middle East and Africa collectively account for close to 10% of treatment access
• Competitive Landscape: The top pharmaceutical manufacturers collectively represent approximately 55% of therapeutic utilization, branded therapies constitute nearly 48% of prescriptions, generic alternatives exceed 52%, and strategic collaborations influence about 20% of pipeline activities.
• Market Segmentation: Hydantoin-based therapies contribute approximately 26% of treatment utilization, benzodiazepines account for 18%, iminostilbenes represent 17%, phenyltriazines contribute 14%, while hospital settings manage nearly 62% of patient treatment episodes.
• Recent Development: Between 2023 and 2025, more than 15% of pipeline updates involved label expansions, approximately 12% focused on pediatric populations, 20% targeted adherence technologies, and 10% addressed seizure-monitoring integration initiatives.

Grand Mal Seizure Market Latest Trends

The Grand Mal Seizure Market Trends indicate a strong transition toward individualized treatment strategies supported by improved diagnostic technologies. Clinical observations suggest that approximately 70% of epilepsy patients can achieve adequate seizure control through antiepileptic medication, while nearly 30% continue to experience breakthrough episodes requiring therapeutic optimization. This pattern has increased physician interest in newer treatment formulations and alternative drug combinations designed to enhance patient outcomes. Digital healthcare integration represents another major development within the Grand Mal Seizure Industry Analysis. Surveys conducted among neurology providers indicate that tele-neurology consultations increased by more than 35% in epilepsy management settings, particularly among patients residing in underserved regions.

The Grand Mal Seizure Market Outlook further highlights increased attention toward pediatric and geriatric populations. Individuals aged 65 years and above account for nearly 24% of newly diagnosed epilepsy cases in developed healthcare systems, while children represent approximately 20% of the active epilepsy population. Pediatric dosage optimization programs have expanded significantly, addressing developmental considerations and improving adherence rates. Generic antiepileptic medications continue to influence prescribing practices. Generic utilization now exceeds 50% of prescriptions in several mature markets, improving treatment accessibility and supporting long-term disease management. Meanwhile, adherence-support technologies, including smartphone applications and reminder systems, have demonstrated improvements in medication compliance ranging from 15% to 25%, contributing to favorable Grand Mal Seizure Market Insights among healthcare stakeholders.

Grand Mal Seizure Market Dynamics

DRIVER

"Rising prevalence of epilepsy and increasing treatment accessibility"

The principal factor supporting Grand Mal Seizure Market Growth is the expanding burden of epilepsy worldwide. Approximately 50 million individuals globally live with epilepsy, with nearly 5 million new diagnoses recorded annually. Generalized tonic-clonic seizures constitute roughly 25% to 35% of seizure classifications, sustaining demand for effective therapeutic interventions. Studies indicate that nearly 70% of patients can achieve seizure control through appropriate medication regimens, demonstrating the critical role of pharmacotherapy. Access to treatment has improved in multiple regions through expanded insurance coverage, generic availability, and increased awareness campaigns. Neurologist referrals have increased by approximately 12% to 18% across several developed healthcare systems. Hospital-based epilepsy units have expanded, with specialized centers exceeding 250 institutions in the United States alone. Educational initiatives targeting patients and caregivers have also contributed to adherence improvements of approximately 20%, supporting favorable Grand Mal Seizure Market Forecast expectations.

RESTRAINT

"Persistent burden of drug-resistant epilepsy"

Drug resistance remains a major limitation affecting the Grand Mal Seizure Market Share. Clinical evidence suggests that approximately 30% of epilepsy patients experience inadequate seizure control despite pharmacological intervention. These individuals frequently require multidrug approaches, dosage adjustments, or consideration of nonpharmacological interventions. Medication-related adverse effects also affect therapeutic continuity. Treatment discontinuation associated with side effects occurs in approximately 10% to 15% of patients, while nonadherence rates may exceed 40% in specific demographic groups. Delayed diagnosis remains problematic, particularly in resource-constrained settings where the treatment gap can exceed 75%. Limited specialist availability in underserved regions further restricts access to optimized care pathways, influencing the overall Grand Mal Seizure Market Opportunities available to healthcare providers and manufacturers.

OPPORTUNITY

"Expansion of precision medicine and advanced monitoring solutions"

Personalized medicine represents a promising avenue within the Grand Mal Seizure Market Research Report. Genetic testing initiatives have expanded significantly, with approximately 15% to 20% of specialized epilepsy centers incorporating genomic assessments into clinical decision-making processes. These tools support individualized treatment selection and may reduce trial-and-error prescribing practices. Wearable seizure-monitoring systems constitute another area of opportunity. Adoption levels have approached 18%, with continued increases expected among patients requiring continuous observation. Remote monitoring programs have demonstrated reductions in emergency visits ranging from 10% to 15% among participating populations. Pediatric formulation development also remains attractive, considering that children account for approximately 20% of epilepsy cases globally. The integration of artificial intelligence into seizure prediction models, currently evaluated in multiple research settings, may further enhance Grand Mal Seizure Industry Report outcomes.

CHALLENGE

"Unequal access to diagnosis and specialist care"

A major challenge confronting the Grand Mal Seizure Market is the uneven distribution of healthcare resources. More than 80% of individuals with epilepsy reside in low- and middle-income countries, yet substantial treatment gaps persist in these regions. In selected countries, up to 75% of epilepsy patients receive inadequate treatment or no treatment at all. Neurologist shortages contribute to delayed intervention, with rural populations experiencing specialist access deficits exceeding 30% compared with urban counterparts. Stigma associated with epilepsy remains another barrier, affecting employment participation in nearly 20% of affected adults and reducing treatment-seeking behavior. Emergency department utilization rates remain elevated among uncontrolled epilepsy populations, with approximately 25% of drug-resistant patients requiring acute care annually. These factors collectively shape Grand Mal Seizure Market Analysis priorities for healthcare systems and pharmaceutical stakeholders.

Segmentation Analysis

The Grand Mal Seizure Market is segmented by treatment type and healthcare application. Hydantoin and benzodiazepine therapies remain widely prescribed due to their effectiveness in seizure control, while nearly 30% of patients require treatment modifications. Hospitals dominate with approximately 62% of treatment utilization, followed by clinics at 21%, academic and research centers at 10%, and other settings contributing the remaining 7%.

Download FREE Sample to learn more about this report.

By Type

Barbiturates: Barbiturates continue to maintain relevance in the Grand Mal Seizure Market despite declining utilization in certain developed healthcare systems. This segment accounts for approximately 9% of therapeutic prescriptions for generalized tonic-clonic seizure management. Phenobarbital remains widely used in resource-constrained environments because of its established efficacy profile and extensive clinical history spanning more than 100 years. The medication is listed among essential therapies in numerous healthcare frameworks and contributes significantly to treatment access in regions where affordability is a priority.

Hydantoin: Hydantoin therapies represent one of the largest segments within the Grand Mal Seizure Market Share, accounting for approximately 26% of global therapeutic utilization. Phenytoin remains the most recognized hydantoin derivative and continues to be prescribed extensively in emergency and maintenance treatment settings. Hospitals utilize hydantoin-based therapies in nearly 40% of acute seizure stabilization cases, emphasizing their clinical importance. Treatment adherence rates associated with hydantoin therapy exceed 65% among patients achieving adequate seizure control. However, long-term administration requires therapeutic drug monitoring, as dosage fluctuations occur in approximately 12% to 18% of patients due to metabolic variability.

Phenyltriazine: Phenyltriazine therapies, led by lamotrigine-based formulations, account for approximately 14% of treatment utilization in the Grand Mal Seizure Market Size. These therapies have gained widespread acceptance because of favorable tolerability profiles and broad-spectrum antiepileptic activity. Neurologists increasingly recommend phenyltriazines for women of childbearing age, with utilization rates in this demographic exceeding 25% in selected clinical practices. Clinical evidence suggests that approximately 60% to 75% of patients treated with phenyltriazine therapies experience meaningful reductions in seizure frequency.

Iminostilbenes: Iminostilbene therapies contribute approximately 17% of the Grand Mal Seizure Market Share, supported by extensive physician familiarity and established treatment outcomes. Carbamazepine remains the leading agent within this category and is frequently prescribed in adult epilepsy populations. Clinical data demonstrate seizure frequency reductions exceeding 65% among appropriately selected patients receiving iminostilbene treatment. Therapeutic monitoring remains important because adverse reactions affect approximately 10% to 20% of users, particularly during early treatment phases. Drug interaction potential also requires careful assessment, especially among elderly patients taking multiple medications.

Benzodiazepines: Benzodiazepines account for approximately 18% of therapeutic interventions within the Grand Mal Seizure Market Analysis, particularly in emergency seizure management and rescue treatment applications. Diazepam, clonazepam, and lorazepam remain frequently utilized agents because of their rapid onset of action. Emergency departments administer benzodiazepines in more than 70% of acute seizure episodes requiring immediate intervention. Short-term effectiveness exceeds 80% in terminating prolonged seizure activity, contributing to their essential role in clinical protocols.

Aliphatic Carboxylic Acid: Aliphatic carboxylic acid therapies, primarily represented by valproate formulations, account for approximately 21% of the Grand Mal Seizure Market Size. Valproate continues to demonstrate broad-spectrum efficacy against generalized tonic-clonic seizures and remains a preferred option in numerous clinical settings. Seizure reduction rates associated with these therapies range between 65% and 80%, reflecting strong therapeutic performance. Prescribing trends vary according to patient demographics, particularly among women of reproductive age due to safety considerations. Utilization among adult male populations exceeds 30% of generalized seizure treatment protocols in selected regions.

Others: The "Others" category represents approximately 5% of overall treatment utilization and includes newer-generation antiepileptic therapies and less frequently prescribed agents. This segment has expanded steadily due to physician interest in individualized treatment strategies for patients experiencing inadequate responses to conventional therapies. Combination regimens involving these therapies account for nearly 12% of multidrug treatment approaches, particularly among individuals with drug-resistant epilepsy. Specialty epilepsy centers report utilization rates approaching 8% to 10% among complex cases requiring personalized intervention.

By Application

Hospitals: Hospitals dominate the Grand Mal Seizure Market, accounting for approximately 62% of application-based utilization. Acute seizure episodes requiring emergency intervention are predominantly managed within hospital environments, where access to neurologists, intensive care facilities, and diagnostic imaging supports comprehensive care. Emergency departments encounter generalized tonic-clonic seizures in nearly 70% of seizure-related admissions requiring urgent treatment. Hospital-based epilepsy monitoring units have expanded significantly, particularly across developed healthcare systems. Continuous electroencephalography utilization has increased by approximately 18%, improving diagnostic precision and treatment optimization.

Clinics: Clinics represent approximately 21% of application demand within the Grand Mal Seizure Market Analysis. Outpatient neurology clinics play a crucial role in long-term disease management, medication titration, and follow-up evaluations. More than 60% of stable epilepsy patients receive routine care through clinic-based settings, reducing reliance on emergency services. Appointment adherence rates exceed 70% among patients participating in structured follow-up programs. Telehealth integration has further enhanced accessibility, with virtual consultations increasing by approximately 35% in neurology practices. Clinics also support patient education initiatives, contributing to medication adherence improvements ranging from 15% to 25%.

Academic and Research Centers: Academic and research centers account for approximately 10% of application utilization, reflecting their contributions to innovation, clinical trials, and specialist consultations. These institutions manage complex cases involving drug-resistant epilepsy, which affects nearly 30% of epilepsy patients worldwide. Clinical trials conducted within academic environments evaluate novel therapies, alternative formulations, and precision medicine approaches. Approximately 20% of investigational epilepsy studies focus on generalized seizure populations. Research centers also contribute to physician education, supporting evidence-based treatment decisions.

Others: Other application settings contribute approximately 7% of the Grand Mal Seizure Market Share and include home healthcare services, rehabilitation facilities, and community-based programs. Home-based care has gained prominence among elderly populations, who represent nearly 24% of newly diagnosed epilepsy cases in developed regions. Caregiver training programs have improved seizure response readiness by approximately 20%, reducing unnecessary emergency visits. Community outreach initiatives support awareness and early recognition efforts, particularly in underserved areas experiencing treatment gaps exceeding 50%. These alternative settings enhance continuity of care and broaden patient access across the Grand Mal Seizure Industry Analysis spectrum.

Regional Outlook

The Grand Mal Seizure Market demonstrates substantial regional variation influenced by disease prevalence, healthcare infrastructure, treatment accessibility, and specialist availability. North America maintains leadership due to advanced diagnostic capabilities and higher treatment penetration. Europe benefits from established reimbursement structures and extensive neurological networks. Asia-Pacific represents a rapidly expanding treatment base because more than half of the global population resides within the region, contributing significantly to epilepsy case volume. Middle East and Africa continue to experience unmet medical needs, with treatment gaps remaining comparatively high.

Download FREE Sample to learn more about this report.

North America

North America remains the largest regional contributor to the Grand Mal Seizure Market Share, accounting for approximately 38% of global therapeutic utilization. The region benefits from a robust healthcare ecosystem, advanced diagnostic technologies, and high levels of epilepsy awareness. In the United States alone, approximately 3.4 million people live with epilepsy, including nearly 470,000 children, while around 150,000 new cases are diagnosed annually. Generalized tonic-clonic seizures account for approximately 30% of epilepsy presentations in tertiary care facilities. The region demonstrates strong treatment penetration, with nearly 90% of diagnosed patients receiving pharmacological therapy. More than 250 specialized epilepsy centers operate across the United States, facilitating multidisciplinary care and advanced monitoring services. Continuous electroencephalography utilization has increased by approximately 20%, supporting earlier diagnosis and optimized medication selection.

Canada also contributes significantly to the Grand Mal Seizure Market Analysis. Epidemiological estimates indicate that approximately 300,000 Canadians live with epilepsy, with incidence rates ranging from 40 to 70 cases per 100,000 population annually. Neurology referral pathways and publicly funded healthcare services enhance treatment continuity and follow-up adherence. Generic antiepileptic medications account for more than 50% of prescriptions throughout North America, improving accessibility and reducing therapy interruptions. Tele-neurology utilization has expanded by approximately 35%, particularly among rural populations where specialist shortages persist. Clinical trial activity remains strong, with North America hosting nearly 30% of global epilepsy studies, reinforcing its position as a leading center for Grand Mal Seizure Market Research Report developments.

Europe

Europe accounts for approximately 28% of the Grand Mal Seizure Market Size, supported by established healthcare frameworks and broad access to neurological services. Across the continent, more than 6 million individuals are estimated to live with epilepsy, while annual incidence rates range between 50 and 70 cases per 100,000 population. Generalized tonic-clonic seizures represent nearly 25% to 30% of diagnosed seizure disorders in European epilepsy registries. Countries such as Germany, France, Italy, Spain, and the United Kingdom maintain well-developed epilepsy care pathways. Specialized epilepsy units have expanded steadily, with hundreds of accredited neurological centers delivering advanced diagnostics and treatment planning. Hospital-based management accounts for approximately 60% of severe seizure episodes, while outpatient clinics oversee long-term follow-up in nearly 65% of stable patients. Medication adherence initiatives have become increasingly prominent throughout Europe.

Structured patient education programs have improved compliance rates by approximately 15% to 20%, contributing to better seizure control outcomes. Generic therapies constitute around 55% of antiepileptic prescriptions, reflecting policies designed to improve treatment affordability. The aging population also influences Grand Mal Seizure Market Trends in Europe. Adults aged 65 years and older account for nearly 25% of new epilepsy diagnoses, creating demand for therapies compatible with multiple comorbidities. Meanwhile, pediatric epilepsy programs continue to expand, as children represent approximately 20% of active epilepsy cases across the region. Research collaborations among academic institutions remain extensive, with Europe participating in approximately 25% of multinational epilepsy clinical investigations. Precision medicine initiatives and digital monitoring technologies continue to gain momentum, strengthening the region's role within the Grand Mal Seizure Industry Report landscape.

Asia-Pacific

Asia-Pacific represents approximately 24% of the Grand Mal Seizure Market Outlook and encompasses the largest patient base globally due to its substantial population size. The region includes countries with diverse healthcare systems, ranging from highly advanced infrastructures to developing economies facing treatment accessibility challenges. Epidemiological assessments suggest that more than 23 million individuals in Asia-Pacific live with epilepsy, accounting for nearly 45% of the global epilepsy burden. The incidence of epilepsy across Asia-Pacific ranges from 40 to 90 cases per 100,000 population annually, with generalized tonic-clonic seizures comprising approximately 30% of reported cases. Countries such as China and India contribute significantly because of their large populations. Together, these two countries account for an estimated 15 million epilepsy patients, representing a considerable proportion of regional demand. Healthcare modernization efforts have improved treatment access.

Generic antiepileptic drugs account for approximately 60% of prescriptions, enabling wider affordability. However, treatment gaps remain substantial in rural areas, where more than 50% of affected individuals may remain untreated due to limited specialist availability and socioeconomic barriers. Japan, South Korea, Australia, and Singapore demonstrate higher treatment penetration rates exceeding 80%, supported by comprehensive healthcare coverage and advanced diagnostic capabilities. Telemedicine expansion has increased neurology consultation accessibility by approximately 30%, particularly in geographically dispersed populations. Academic institutions throughout Asia-Pacific are increasingly active in epilepsy research, contributing to approximately 20% of ongoing international studies. Pediatric epilepsy services are also expanding, given that children account for nearly 22% of epilepsy patients in several countries across the region. These developments support favorable Grand Mal Seizure Market Opportunities and long-term therapeutic demand.

Middle East & Africa

The Middle East & Africa region accounts for approximately 10% of the Grand Mal Seizure Market Share, characterized by significant disparities in healthcare infrastructure and treatment availability. Epidemiological estimates indicate that more than 5 million individuals across the region live with epilepsy, with incidence rates ranging from 45 to 80 cases per 100,000 population annually. One of the defining characteristics of this region is the persistence of treatment gaps. In certain low-resource settings, more than 70% of epilepsy patients do not receive adequate treatment, largely because of shortages in neurological specialists, medication accessibility issues, and social stigma. Rural communities experience specialist deficits exceeding 40% compared with urban centers. Countries within the Gulf Cooperation Council have made measurable progress in epilepsy care. Treatment penetration rates in these healthcare systems approach 75% to 85%, supported by investments in tertiary hospitals and neurological services.

Advanced diagnostic modalities, including electroencephalography and neuroimaging, are increasingly available in metropolitan healthcare facilities. Sub-Saharan African nations continue to face significant challenges. Infectious diseases, perinatal complications, and traumatic brain injuries contribute to epilepsy incidence rates exceeding 70 cases per 100,000 population in selected areas. Community-based awareness programs have improved early recognition by approximately 15%, although access barriers remain substantial. Generic antiepileptic medications account for nearly 65% of dispensed therapies, reflecting affordability priorities throughout the region. International collaborations and non-governmental initiatives have supported healthcare worker training programs, improving seizure identification and management competencies by approximately 20%. These efforts are expected to influence future Grand Mal Seizure Market Growth through enhanced diagnosis and expanded treatment accessibility.

Two Top Companies with the Highest Market Share

• UCB Celltech – Estimated to account for approximately 18% to 20% of branded therapeutic utilization, supported by an established neurology portfolio and broad international presence across more than 40 countries.
• Johnson & Johnson – Represents approximately 14% to 16% of branded market utilization, benefiting from extensive neurological expertise, diversified product availability, and distribution capabilities spanning over 60 markets worldwide.

Investment Analysis and Opportunities

The Grand Mal Seizure Market continues to attract strategic investments aimed at improving therapeutic outcomes, expanding treatment accessibility, and advancing precision medicine initiatives. Approximately 30% of epilepsy patients worldwide remain inadequately controlled, creating a significant opportunity for innovation in drug development and supportive technologies. Investment activity increasingly targets digital health integration. Wearable seizure-monitoring technologies have demonstrated adoption rates approaching 18% to 20%, encouraging further funding in predictive analytics and remote patient monitoring platforms. Tele-neurology services have expanded by approximately 35%, highlighting opportunities for healthcare providers and technology developers to improve specialist access in underserved regions.

Research investments are also directed toward genetic and biomarker-driven treatment strategies. Around 15% to 20% of specialized epilepsy centers now incorporate genomic assessments into clinical practice, suggesting growing demand for personalized medicine solutions. Pediatric epilepsy represents another attractive segment, as children account for nearly 20% of the active epilepsy population, necessitating age-appropriate formulations and dosing strategies. Emerging economies offer substantial growth opportunities because treatment gaps exceed 50% in several low-resource settings. Expansion of generic manufacturing capabilities, physician education initiatives, and public awareness campaigns may significantly improve treatment penetration. Academic collaborations further support pipeline advancement, with approximately 20% of investigational epilepsy programs focusing on generalized seizure populations, reinforcing the long-term potential of the Grand Mal Seizure Market Forecast.

Two Top Companies with the Highest Market Share

• UCB Celltech – Estimated to account for approximately 18% to 20% of branded therapeutic utilization, supported by an established neurology portfolio and broad international presence across more than 40 countries.
• Johnson & Johnson – Represents approximately 14% to 16% of branded market utilization, benefiting from extensive neurological expertise, diversified product availability, and distribution capabilities spanning over 60 markets worldwide.

Investment Analysis and Opportunities

The Grand Mal Seizure Market continues to attract strategic investments aimed at improving therapeutic outcomes, expanding treatment accessibility, and advancing precision medicine initiatives. Approximately 30% of epilepsy patients worldwide remain inadequately controlled, creating a significant opportunity for innovation in drug development and supportive technologies. Investment activity increasingly targets digital health integration. Wearable seizure-monitoring technologies have demonstrated adoption rates approaching 18% to 20%, encouraging further funding in predictive analytics and remote patient monitoring platforms. Tele-neurology services have expanded by approximately 35%, highlighting opportunities for healthcare providers and technology developers to improve specialist access in underserved regions.

Research investments are also directed toward genet